Carbapenem-resistant organisms: Difference between revisions
From IDWiki
(Created page with "== Background == * Mechanisms include decreased expression of porins, increased expression of efflux pumps, and carbapenemases == Management == === Novel Antibiotics ==...") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | ==Background== |
| − | * |
+ | *Mechanisms include decreased expression of porins, increased expression of efflux pumps, and [[carbapenemases]] |
| − | == |
+ | ==Management== |
| − | |||
| − | === Novel Antibiotics === |
||
{| class="wikitable" |
{| class="wikitable" |
||
!Antibiotic |
!Antibiotic |
||
| Line 103: | Line 101: | ||
| style="color:darkgreen;text-align:center" | + |
| style="color:darkgreen;text-align:center" | + |
||
|} |
|} |
||
| ⚫ | |||
| − | |||
| ⚫ | |||
Revision as of 08:15, 21 September 2020
Background
- Mechanisms include decreased expression of porins, increased expression of efflux pumps, and carbapenemases
Management
| Antibiotic | KPC | NDM | OXA-48 | CRPsA | CRAcB | Stenotrophomonas |
|---|---|---|---|---|---|---|
| aztreonam-avibactam | + | + | + | ± | – | + |
| cefiderocol | + | + | + | + | + | + |
| ceftazidime-avibactam | + | – | + | ± | – | – |
| ceftolozane-tazobactam | – | – | – | ± | – | ± |
| eravacycline | + | + | + | – | + | + |
| fosfomycin | ± | ± | ± | ± | – | – |
| imipenem-relebactam | + | – | ± | + | – | – |
| meropenem-vaborbactam | + | – | – | – | – | – |
| plazomicin | + | ± | + | ± | – | – |
| colistin | ± | ± | ± | ± | ± | ± |
| tigecycline | + | + | + | – | + | + |
